Colorectal Cancer Screening Rates Still Low: CDC Study Finds

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 5
Volume 10
Issue 5

WASHINGTON-Colorectal cancer screening rates have risen slightly since 1997 but remain at low levels, according to a report by the Centers for Disease Control and Prevention. The report compared data from the 1999 Behavioral Risk Factor Surveillance System (BRFSS)-a random-digit phone survey of residents of the United States and Puerto Rico-with findings from the 1997 BRFSS. Respondents over age 50 were asked about colorectal cancer screening.

WASHINGTON—Colorectal cancer screening rates have risen slightly since 1997 but remain at low levels, according to a report by the Centers for Disease Control and Prevention. The report compared data from the 1999 Behavioral Risk Factor Surveillance System (BRFSS)—a random-digit phone survey of residents of the United States and Puerto Rico—with findings from the 1997 BRFSS. Respondents over age 50 were asked about colorectal cancer screening.

In 1999, 44% of the respondents reported receiving either a fecal occult blood test (FOBT) in the year before being surveyed and/or a sigmoidoscopy or colonoscopy exam within the previous 5 years, compared with 41% in 1997 who reported getting an FOBT and/or sigmoidoscopy or proctoscopy within the same time spans.

The highest FOBT use in the 1999 survey was in the District of Columbia (36.4%) and the lowest was in Puerto Rico (8.2%). For sigmoidoscopy/colon-oscopy, the high was 46.1% in Delaware and the low 20.4% in Puerto Rico.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.